Emerald Mutual Fund Advisers Trust Sells 166,165 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Emerald Mutual Fund Advisers Trust cut its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 13.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,067,400 shares of the medical research company's stock after selling 166,165 shares during the period. Emerald Mutual Fund Advisers Trust owned 0.83% of NeoGenomics worth $17,591,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in NEO. Nordea Investment Management AB grew its position in shares of NeoGenomics by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company's stock valued at $1,301,000 after purchasing an additional 2,125 shares during the last quarter. Swiss National Bank increased its stake in NeoGenomics by 1.0% in the fourth quarter. Swiss National Bank now owns 252,100 shares of the medical research company's stock valued at $4,155,000 after acquiring an additional 2,600 shares during the period. Jennison Associates LLC grew its position in NeoGenomics by 18.7% in the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock valued at $24,963,000 after acquiring an additional 238,288 shares during the period. Rhumbline Advisers increased its position in shares of NeoGenomics by 2.4% during the 4th quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company's stock worth $6,411,000 after purchasing an additional 9,098 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of NeoGenomics by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,161,352 shares of the medical research company's stock valued at $19,139,000 after acquiring an additional 26,701 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Stock Up 6.1 %

Shares of NEO stock traded up $0.44 on Friday, reaching $7.70. 3,644,552 shares of the company were exchanged, compared to its average volume of 1,075,572. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The company has a 50-day moving average of $9.40 and a 200-day moving average of $13.27. The company has a market cap of $990.66 million, a price-to-earnings ratio of -12.42 and a beta of 1.41. NeoGenomics, Inc. has a one year low of $6.08 and a one year high of $19.12.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm had revenue of $168.04 million for the quarter, compared to the consensus estimate of $171.38 million. During the same quarter in the prior year, the firm earned ($0.02) EPS. The company's revenue was up 7.6% compared to the same quarter last year. Analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on NEO shares. Needham & Company LLC cut their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a report on Tuesday. Piper Sandler decreased their price target on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Leerink Partnrs downgraded shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Leerink Partners lowered shares of NeoGenomics from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $25.00 to $9.00 in a research report on Wednesday. Finally, Morgan Stanley dropped their price objective on NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating for the company in a report on Thursday. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, NeoGenomics presently has a consensus rating of "Moderate Buy" and an average target price of $14.50.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.